Trevi Therapeutics Schedules Q2 2026 Earnings and Corporate Update — Trevi Therapeutics, Inc.

Event summary

Trevi Therapeutics will report Q2 2026 financial results on August 6, 2026.
The company is developing Haduvio™ (oral nalbuphine ER) for chronic cough in IPF, non-IPF ILD, and RCC patients.
Haduvio showed statistically significant reduction in cough frequency in clinical trials.
No FDA-approved therapies currently exist for these conditions.

The big picture

Trevi Therapeutics is operating in a niche but critical area of respiratory medicine where chronic cough remains untreated. The company's focus on Haduvio™ (oral nalbuphine ER) targets a growing patient population with IPF, non-IPF ILD, and RCC, conditions that currently lack FDA-approved treatments. The strategic anomaly here is the dual challenge of proving efficacy in multiple indications while navigating regulatory pathways for a novel therapy.

What we're watching

Regulatory Pathway: Whether Trevi can secure FDA approval for Haduvio given the lack of current therapies in this space.
Clinical Validation: The pace at which additional clinical data will be released to support Haduvio's efficacy claims.
Market Opportunity: How Trevi positions Haduvio in a market with significant unmet need across multiple patient populations.